Howland Capital Management LLC Has $4.19 Million Position in AbbVie Inc. (NYSE:ABBV)

Howland Capital Management LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 0.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,579 shares of the company’s stock after acquiring an additional 95 shares during the period. Howland Capital Management LLC’s holdings in AbbVie were worth $4,190,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Quotient Wealth Partners LLC boosted its position in AbbVie by 14.4% in the fourth quarter. Quotient Wealth Partners LLC now owns 7,182 shares of the company’s stock valued at $1,276,000 after buying an additional 902 shares in the last quarter. Northeast Investment Management boosted its position in AbbVie by 1.2% in the fourth quarter. Northeast Investment Management now owns 12,111 shares of the company’s stock valued at $2,152,000 after buying an additional 147 shares in the last quarter. Benedict Financial Advisors Inc. boosted its position in AbbVie by 0.6% in the fourth quarter. Benedict Financial Advisors Inc. now owns 45,850 shares of the company’s stock valued at $8,148,000 after buying an additional 256 shares in the last quarter. Summit Wealth & Retirement Planning Inc. boosted its position in AbbVie by 16.4% in the fourth quarter. Summit Wealth & Retirement Planning Inc. now owns 1,455 shares of the company’s stock valued at $259,000 after buying an additional 205 shares in the last quarter. Finally, Richard C. Young & CO. LTD. boosted its position in AbbVie by 8.7% in the fourth quarter. Richard C. Young & CO. LTD. now owns 25,137 shares of the company’s stock valued at $4,467,000 after buying an additional 2,014 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ABBV shares. Daiwa America lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 5th. Sanford C. Bernstein began coverage on shares of AbbVie in a research report on Thursday, October 17th. They issued a “market perform” rating and a $203.00 price target on the stock. JPMorgan Chase & Co. dropped their target price on shares of AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. Daiwa Capital Markets downgraded shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price for the company. in a research note on Thursday, December 5th. Finally, Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $208.35.

Insider Buying and Selling

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.25% of the stock is currently owned by company insiders.

AbbVie Trading Down 1.2 %

ABBV opened at $190.67 on Friday. The firm’s fifty day moving average is $177.54 and its two-hundred day moving average is $185.60. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. The firm has a market cap of $336.94 billion, a PE ratio of 79.45, a price-to-earnings-growth ratio of 1.53 and a beta of 0.58. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter last year, the business earned $2.79 earnings per share. Equities research analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current year.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.